Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovasave
- Development stage
- Phase 2
- Lead developer
- Sangamo Therapeutics
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Ovasave is an antigen-specific autologous T regulatory somatic cell therapy developed for the treatment of inflammatory bowel disease, specifically refractory Crohn’s disease. It involves the use of ovalbumin-specific autologous regulatory T cells (Ova-Treg) administered intravenously to modulate immune response and reduce inflammation in patients with severe Crohn’s disease. The therapy aims to restore immune tolerance by expanding antigen-specific regulatory T cells that suppress pathological inflammation. Ovasave was developed by TxCell and has undergone clinical trials including a randomized controlled phase IIb study (CATS29) designed to evaluate its efficacy and safety in patients with refractory Crohn’s disease. The FDA granted Fast Track Designation to Ovasave for moderate to severe Crohn’s disease, reflecting its potential to address unmet medical needs in this patient population[3][5][6].
- Brand names
- Ovasave
Beyond the preview
Go deeper on Ovasave.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovasave.